Development Level

Tbio 27 | 11,445
Tchem 3 | 1,598
Tdark 1 | 6,588

IMPC Phenotype

preweaning lethality, complete... 2 | 979
abnormal behavior 1 | 298
abnormal coat- hair morphology 1 | 19
abnormal cranium morphology 1 | 36
abnormal eye morphology 1 | 68
abnormal retina morphology 1 | 71
decreased IgG1 level 1 | 8
decreased IgG2b level 1 | 4
decreased circulating serum al... 1 | 82
decreased circulating triglyce... 1 | 79
decreased granulocyte number 1 | 6
decreased heart left ventricle... 1 | 28
decreased spleen weight 1 | 10
decreased vertical activity 1 | 208
embryonic lethality prior to o... 1 | 239
embryonic lethality prior to t... 1 | 278
enlarged kidney 1 | 14
enlarged lymph nodes 1 | 37
hyperactivity 1 | 148
increased circulating alkaline... 1 | 122
increased circulating calcium ... 1 | 34
increased circulating choleste... 1 | 66
increased circulating phosphat... 1 | 26
increased neutrophil cell numb... 1 | 46
increased spleen weight 1 | 10
increased startle reflex 1 | 112
preweaning lethality, incomple... 1 | 499
short tibia 1 | 97
thin ventricular wall 1 | 24

Disease

Carcinoma 27 | 11,493
glioblastoma 19 | 5,792
medulloblastoma, large-cell 17 | 6,241
ovarian cancer 17 | 8,520
osteosarcoma 16 | 7,950
Kidney cancer 14 | 2,613
atypical teratoid / rhabdoid tumor 14 | 5,112
psoriasis 14 | 6,694
adult high grade glioma 13 | 3,801
primitive neuroectodermal tumor 13 | 3,035
ependymoma 12 | 4,679
lung cancer 12 | 4,740
Astrocytoma, Pilocytic 11 | 3,081
Cancer 11 | 2,499
astrocytic glioma 11 | 2,597
group 3 medulloblastoma 11 | 4,104
oligodendroglioma 10 | 2,850
Intellectual disability 9 | 1,016
subependymal giant cell astrocytoma 9 | 2,287
Pick disease 8 | 1,894
group 4 medulloblastoma 8 | 1,855
malignant mesothelioma 8 | 3,232
intraductal papillary-mucinous adenoma (IPMA) 7 | 2,955
intraductal papillary-mucinous carcinoma (IPMC) 7 | 2,989
invasive ductal carcinoma 7 | 2,951
lung carcinoma 7 | 2,843
colon cancer 6 | 1,478
ductal carcinoma in situ 6 | 1,745
interstitial cystitis 6 | 2,312
intraductal papillary-mucinous neoplasm (IPMN) 6 | 3,291
lung adenocarcinoma 6 | 2,716
non-small cell lung cancer 6 | 2,890
aldosterone-producing adenoma 5 | 665
pancreatic cancer 5 | 2,398
ulcerative colitis 5 | 1,819
Aarskog syndrome 4 | 12
Breast cancer 4 | 3,578
Schizophrenia 4 | 1,160
adrenocortical carcinoma 4 | 1,428
breast carcinoma 4 | 1,638
pituitary cancer 4 | 1,972
primary Sjogren syndrome 4 | 735
tuberculosis 4 | 2,010
Breast Neoplasms 3 | 445
Cardiovascular system disease 3 | 246
Chronic Lymphocytic Leukemia 3 | 262
Dull intelligence 3 | 645
Hypertensive disease 3 | 292
Low intelligence 3 | 645
Mammary Neoplasms 3 | 425
Mental Retardation 3 | 645
Mental deficiency 3 | 645
Poor school performance 3 | 645
Prostatic Neoplasms 3 | 495
Skin cancer 3 | 469
X- linked recessive 3 | 110
astrocytoma 3 | 1,146
cystic fibrosis 3 | 1,696
dermatomyositis 3 | 966
diabetes mellitus 3 | 1,728
hepatocellular carcinoma 3 | 547
pediatric high grade glioma 3 | 1,064
progressive supranuclear palsy 3 | 676
Abdominal Pain 2 | 98
Animal Mammary Neoplasms 2 | 136
Atopic dermatitis 2 | 952
Attention Deficit Disorder with Hyperactivity 2 | 21
Attention deficit hyperactivity disorder 2 | 278
Autistic Disorder 2 | 364
Bipolar Disorder 2 | 666
Brachydactyly 2 | 156
Carcinoma, Hepatocellular 2 | 228
Cell Transformation, Neoplastic 2 | 97
Colorectal Neoplasms 2 | 243
Down syndrome 2 | 499
Endometrial cancer 2 | 311
Endometriosis 2 | 540
Failure to gain weight 2 | 365
HIV Infections 2 | 102
Hypertension 2 | 396
Keloid 2 | 37
Liver cancer 2 | 604
Liver carcinoma 2 | 240
Lymphoid leukemia 2 | 160
Mammary Neoplasms, Animal 2 | 136
Melanoma 2 | 711
Mental Retardation, X-Linked 2 | 23
Neoplasm Metastasis 2 | 168
Pediatric failure to thrive 2 | 365
Polycystic ovary syndrome 2 | 360
Waldenstrons macroglobulinemia 2 | 765
acute quadriplegic myopathy 2 | 1,158
cystic fibrosis and chronic rhinosinusitis 2 | 214
gastric carcinoma 2 | 807
juvenile dermatomyositis 2 | 1,187
medulloblastoma 2 | 720
mucosa-associated lymphoid tissue lymphoma 2 | 484
non diabetic and post-ischemic heart failure 2 | 200
non-small cell lung carcinoma 2 | 317
spina bifida 2 | 1,074

Tissue

Blood and immune system 31 | 16,909
Cardiovascular System 31 | 15,192
Digestive Tract 31 | 17,369
Endocrine System 31 | 18,159
Female tissues 31 | 17,400
Liver and Pancreas 31 | 16,750
Male tissues 31 | 17,142
Nervous System 31 | 16,725
Respiratory system 31 | 16,393
Skin and soft tissues 31 | 17,230
Urinary Tract 31 | 16,678

Target Family

Non-IDG 23 | 12,091
Enzyme 7 | 4,145
Kinase 1 | 634

PathwayCommons: pid Pathway

http://pathwaycommons.org/pc2/... 31 | 31
http://pathwaycommons.org/pc2/... 137 | 137
http://pathwaycommons.org/pc2/... 125 | 125
http://pathwaycommons.org/pc2/... 102 | 102
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 85 | 85
http://pathwaycommons.org/pc2/... 82 | 82
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 77 | 77
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 69 | 69
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 62 | 62
http://pathwaycommons.org/pc2/... 61 | 61
http://pathwaycommons.org/pc2/... 60 | 60
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 58 | 58
http://pathwaycommons.org/pc2/... 57 | 57
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 55 | 55
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 51 | 51
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 44 | 44
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 41 | 41
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 36 | 36

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
ARF GTPase-activating protein GIT1 GIT1 Tbio Enzyme -1.84352 75.7 358
Guanine nucleotide exchange factor DBS MCF2L Tbio Non-IDG -0.98363 12.4 115
Dedicator of cytokinesis protein 9 DOCK9 Tbio Non-IDG -0.77983 6.21 37
Rho GDP-dissociation inhibitor 1 ARHGDIA Tchem Non-IDG -2.56885 370.1 382
Nucleoside diphosphate kinase A NME1 Tbio Kinase -2.99077 863.1 945
Rho guanine nucleotide exchange factor 9 ARHGEF9 Tbio Non-IDG -1.48568 33.8 126
Intersectin-2 ITSN2 Tbio Non-IDG -2.55501 357.2 49
Rho guanine nucleotide exchange factor 25 ARHGEF25 Tbio Non-IDG -1.43926 31.5 50
FYVE, RhoGEF and PH domain-containing protein 1 FGD1 Tbio Non-IDG -2.02545 109.7 42
Rho GTPase-activating protein 10 ARHGAP10 Tbio Enzyme -1.35140 20.2 78